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Bone resorption and homeostasis is carried out by osteoclasts, whose differentiation
and activity are regulated by the RANK/RANKL axis. Our previous studies using a
mouse model of joint injury show that joint trauma induces local inflammation followed
by bone remodeling. The transcription factor cyclin-dependent kinase 9 (CDK9) is
the major regulator of inflammation, as CDK9 inhibitor flavopiridol effectively suppress
injury-induced inflammatory response. The objective of this study was to investigate
the underlying mechanism through which flavopiridol regulates bone resorption. The
effects of CDK9 inhibition, by the specific-inhibitor flavopiridol, on bone resorption were
determined in vivo using two distinct and clinically relevant bone remodeling models.
The first model involved titanium particle-induced acute osteolysis, and the second
model was ovariectomy-induced chronic osteoporosis. The effects and mechanism
of CDK9 inhibition on osteoclastogenesis were examined using in vitro culture of
bone marrow macrophages (BMMs). Our results indicated that flavopiridol potently
suppressed bone resorption in both in vivo bone-remodeling models. In addition, CDK9
inhibition suppressed in vitro osteoclastogenesis of BMM and reduced their expression
of osteoclast-specific genes. Finally, we determined that flavopiridol suppressed RANKL
signaling pathway via inhibition of p65 phosphorylation and nuclear translocation of
NF-κB. Summary, CDK9 is a potential therapeutic target to prevent osteolysis and
osteoporosis by flavopiridol treatment.
Keywords: flavopiridol, CDK9, osteoclast, bone resorption, NF-κB
INTRODUCTION
Bone tissue homeostasis is maintained by the dynamic balance between osteoblastic bone
formation and osteoclastic bone resorption (Seeman and Delmas, 2006). This balance is vulnerable
to influence by physical, endocrine and paracrine stimuli under various physiological and
pathological conditions. In some circumstances like aging, osteoarthritis, and endocrine diseases,
the equilibrium is disturbed and results in an imbalance between bone formation and resorption,
leading to metabolic diseases such as osteopetrosis and osteoporosis (Eastell et al., 2016).
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Recent studies have demonstrated that the resorption or
remodeling of bone tissue mainly depends on the differentiation
of osteoclasts (Boyce et al., 2009), which is regulated by
two essential cytokines, namely macrophage colony-stimulating
factor (M-CSF) and receptor activator of nuclear factor
kappa B ligand (RANKL) (Abu-Amer, 2013; Sucur et al.,
2014). Osteoclasts are multi-nucleated cells derived from
hematopoietic stem cells of monocytic lineage. M-CSF plays
a central role in directing hematopoietic stem cells into the
monocyte/macrophage lineage, and also in up-regulating RANK
expression, which is required for osteoclast differentiation.
RANKL is a transmembrane protein that belongs to the tumor
necrosis factor (TNF) superfamily that is closely associated with
both acute and chronic inflammation (Boyce and Xing, 2008;
Xing et al., 2012).
Inflammation is a biological response to stressful events that
trigger the transcriptional activation of primary inflammatory
response genes (Hargreaves et al., 2009; Zippo et al., 2009).
In the absence of inflammatory stimuli, transcription of these
genes has already been pre-initiated by RNA polymerase II,
but its progress is soon blocked before transcription can
enter the elongation stage (Yamaguchi et al., 2013). During
a stress response, the transcription factor cyclin-dependent
kinase 9 (CDK9) is rapidly recruited to the promoter to
phosphorylate RNA polymerase II, which then escapes promoter-
proximal pausing and proceed to synthesize full-length mRNAs
(Hargreaves et al., 2009; Zippo et al., 2009; Chen et al.,
2014). Hence, CDK9 represents a key target for suppressing
inflammatory gene activation to effectively modulate the
inflammatory response.
In our previous studies (Yik et al., 2014; Christiansen et al.,
2015; Hu et al., 2016), we discovered that inflammatory stimuli,
such as a knee joint injury, resulted in marked up-regulation of
pro-inflammatory cytokines like IL-1β, IL-6, and TNF-α. This
cytokine up-regulation is followed by a substantial subchondral
bone remodeling that potentiates osteoarthritis. Importantly,
we find that CDK9 inhibition by flavopiridol prevents the
induction of pro-inflammatory cytokines, this demonstrates the
anti-inflammatory effect of flavopiridol is due to its ability
to suppress transactivation of inflammatory genes (Yik et al.,
2014). Furthermore, numerous studies (Sucur et al., 2014; Cauley
et al., 2016) indicate that osteoclastogenesis is induced under
inflammatory condition. This suggests a possible connection
between flavopiridol’s function in inflammatory gene expression,
bone loss, and osteoclastogenesis.
CDK9 has long been recognized as an important factor in
regulating NF-κB activity (Barboric et al., 2001). Given the
well-known role of NF-κB in inflammation and in RANKL
signaling in osteoclast formation, we investigated the roles of
CDK9 in osteoclast function, using two in vivo mouse models of
bone remodeling: (1) acute titanium particles-induced osteolysis,
and (2) chronic estrogen deficiency-induced osteoporosis.
We also determined the molecular mechanism of the bone
protective effect of flavopiridol treatment, by investigating the
effects of flavopiridol treatment on NF-κB/RANKL signaling
and osteoclastogenesis of bone marrow macrophages (BMMs)
in vitro.
MATERIALS AND METHODS
Titanium Particles
Pure titanium (Ti) particles (1–3 µm diameter) were obtained
from Johnson Mathey Chemicals (Ward Hill, MA, United States)
and prepared by continuous washing in 100% ethanol for 48 h to
remove endotoxins. The Ti-particles were then re-suspended in
sterile PBS at a concentration of 300 mg/mL and stored at 4◦C.
The endotoxin level of particle suspension was undetectable as
determined by a Limulus assay (Biowhittaker, Walkersville, MD,
United States), according to the manufacturer’s instructions.
Flavopiridol Injection
The small molecule CDK9 inhibitor Flavopiridol (Sigma-
Aldrich, St. Louis, MO, United States) was dissolved in
DMSO to a stock concentration of 5 mg/ml. Flavopiridol
(7.5 mg/kg) diluted in sterile saline was administered locally
(osteolysis) or intraperitoneally (ovariectomy) via a 30-gauge
needle immediately after animal surgery. Thereafter, the drug
was administered daily for up to 14 days for the calvarial
osteolysis model, or three times weekly for up to 8 weeks for the
ovariectomy model. Control untreated animals received saline
injections only.
Calvarial Osteolysis Model
Animal studies were conducted in accordance with the principles
and procedures approved by the Animal Care Committee of
Sir Run Run Shaw Hospital, Zhejiang University. The in vivo
mouse calvaria experiments were then performed. Briefly, healthy
8-week old female C57BL/6 mice were randomly assigned into
three groups (n = 6 each group): sham operated with PBS control
(sham), Ti-particles with PBS (vehicle), and Ti-particles with
flavopiridol (7.5 mg/kg). After anesthesia, a midline incision was
made to the calvaria; the periosteum was then scratched and
lifted to expose the middle suture of the calvaria. 30 mg of Ti-
particles was then embedded, with vehicle or flavopiridol. The
incision was closed sterilely. No mortality was observed during
or after particle implantation. Mice were able to retain normal
activity throughout the duration of the experiment. 50 µl of PBS
or flavopiridol (7.5 mg/kg) was subcutaneously injected into the
surgical implant site daily. Mice were sacrificed at 3-, 7-, and
14-day post-operation, and the calvaria samples were harvested
thereafter. The degree of particle-induced osteolysis was assessed
using high-resolution micro-computed tomography (µCT) and
histological staining.
Mouse Ovariectomy Model
12-week old C57BL/6 female mice were generally anesthetized
and subjected to either a sham operation or bilateral ovariectomy
(OVX). Mice were randomly divided into three groups (n = 6
each group): sham (sham operation with PBS injection), vehicle
(OVX with PBS injection), and CDK9 inhibitor (OVX with
7.5 mg/kg flavopiridol injection). 100 µl of each solution was
injected intraperitoneally, three times a week for 8 weeks. All
mice were then sacrificed at the end. Mouse body weights were
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recorded weekly, and uteri were isolated and weighed at the end-
point to confirm the effects of OVX. Right femurs were processed
for µCT analyses.
Micro-CT Scanning
After mice were sacrificed, the calvaria or right femurs were
harvested and fixed in 4% formaldehyde in PBS (pH 7.4) for
24 h and then analyzed using high resolution µCT (Skyscan
1072; Skyscan, Aartselaar, Belgium) with following settings:
X-ray voltage, 50 kV; electric current, 500 mA; rotation step,
0.7. To reduce metal artifacts, the implanted Ti-particles were
removed by thorough washing with PBS before µCT scanning.
Scans were performed at 9-nm intervals. After reconstruction,
a square region of interest around the midline suture of the
calvarium or trabecular bone at the distal femoral epiphysis was
chosen for qualitative and quantitative analysis. The bone volume
to tissue volume ratio (BV/TV), trabecular number (Tb.N),
trabecular thickness (Tb.Th), and trabecular spacing (Tb.Sp)
were measured using the resident reconstruction program
(Skyscan).
Histological and Histomorphometric
Analysis
After µCT scanning, the calvaria samples were decalcified in a
sonic decalcification machine (DeCa Dx-100, Pro-cure medical
technology, HK) for 1 day, and then embedded in paraffin.
Histological sections were prepared for hematoxylin and eosin
(H&E), as well as TRAP staining. Six sections per group were then
examined with a microscope (Fujifilm, Tokyo, Japan) using 4, 10,
and 20X objectives.
Mouse BMM Preparation and in Vitro
Osteoclastogenesis
Primary bone marrow stromal cells (BMSCs) were isolated from
bone marrow aspirates from hind legs of 6-week old, female
C57BL/6 mice. Briefly, cells were harvested from the femoral and
tibia bone marrow and cultured in complete medium: α-MEM
(Genom, Biotech., Hangzhou, Zhejiang, China) supplemented
with 10% FBS, 1% penicillin/streptomycin, and 30 ng/mL M-CSF
[A kind gift from and produced by Dr. An Qin’s lab (Zhai et al.,
2014)] in a 37◦C, 5% CO2 incubator. Cells were cultured for
several days and washed with PBS during medium changes every
other day to remove non-adherent cells. At ∼90% confluence,
cells were washed with PBS three times and then trypsinized
for 30 min to harvest the adherent BMMs. BMMs were then
plated in 96-well plates at a density of 8 × 103 cells/well, in
triplicates, and cultured for 24 h. Cells were then treated with
various concentrations of flavopiridol (0, 50, 100, or 200 nM)
plus M-CSF (30 ng/mL), and RANKL (50 ng/mL) [A kind gift
from and produced by Dr. An Qin’s lab (Zhai et al., 2014)];
media was changed every other day. After 5 days, cells were
fixed and stained for TRAP activity. The numbers of TRAP
positive multi-nucleated osteoclasts and the percentage of area
occupied by osteoclasts relative to total area were determined
using Image-Pro Plus software (Media Cybernetics, Bethesda,
MD, United States).
Cell Viability Assay
The anti-proliferative effect of CDK9 inhibition on BMMs was
assessed with a cell counting kit-8 (CCK-8, Sigma-Aldrich,
St. Louis, MO, United States) according to the manufacturer’s
instructions. BMMs were plated in 96-well plates at a density
of 2 × 104 cells/well, in triplicates, and cultured in 100 µL
complete α-MEM medium with 30 ng/mL M-CSF in the presence
of different concentrations of flavopiridol for 24-, 48-, and 72-
h. After washing three times with PBS, 10 µL CCK-8 buffer was
added to each well, and incubated for 2 h. The absorbance at
450 nm (630 nm as reference) was measured with a plate reader
(ELX800, Bio-Tek, Winooski, VT, United States).
Bone Resorption Pit Assay
Bone marrow macrophages were seeded at a density of 8 × 103
cells/well containing bovine bone slice (5 mm × 5 mm) (A kind
gift from and produced by Dr. An Qin’s lab) in a 96-well plate in
triplicates. After 24 h, cells were treated with 50 ng/mL RANKL,
30 ng/mL M-CSF, and 0 or 200 nM flavopiridol for 5 days.
Cells adhered to bone slices were then removed by mechanical
agitation and sonication. Resorption pits were visualized under
a scanning electron microscopy (SEM; FEI Instr., Hillsboro, OR,
United States), and the bone resorption area (darker shades) was
quantified using Image J software (National Institutes of Health,
Bethesda, MD, United States).
Quantitative Polymerase Chain Reaction
(PCR) Analysis
For the determination of mRNA expression, 10 × 104
BMMs were seeded in 24-well plate and cultured in complete
α-MEM medium containing M-CSF (30 ng/mL) and RANKL
(50 ng/mL). Cells were then treated with or without flavopiridol
(200 nM) for various times, and harvested by scraping and
transferred to Eppendorf tubes, followed by cell lysis, total
RNA isolation, and reverse transcription to generate cDNA,
using the RNeasy Minikit (Qiagen, Valencia, CA, United States)
and HIFIScript cDNA synthesis kit (CWBio, Beijing, China)
according to the manufacturer’s instructions. 4 µl of cDNA
was used for quantitative real time-PCR (in a final volume
of 20 µl) performed in triplicate in an ABI Prism 7500
system (Applied Biosystems, Foster City, CA, United States)
with SsoFast EvaGreen supermix (Bio-Rad, Hercules, CA,
United States) according to the manufacturer’s conditions.
mRNAs of interest and the housekeeping genes were amplified
with equal efficiencies, results were normalized to 18S rRNA
and calculated as fold-change in mRNA expression relative to
untreated control. Probes used to detect mouse cDNAs are as
follow:
18S:
Forward, 5′-AGGGGAGAGCGGGTAAGAGA-3′,
Reverse, 5′-GGACAGGACTAGGCGGAACA-3′;
NFATc1:
Forward, 5′-TCCACCCACTTCTGACTTCC-3′,
Reverse, 5′-AAGGCAGAATCATGGACGAC-3′;
TRAP:
Forward, 5′-CCATTGTTAGCCACATACGG-3′,-
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Reverse, 5′-CACTCAGCACATAGCCCACA-3′;
cathepsin K (CTSK):
Forward, 5′-TCCGCAATCCTTACCGAATA-3′,
Reverse, 5′-AACTTGAACACCCACATCCTG-3′;
CTR:
Forward, 5′-ACCATTATCCACGCCATCAC-3′,
Reverse, 5′-GAAGAAGTTGACCACCAGAGC-3′;
c-Fos:
Forward, 5′-GTTCGTGAAACACACCAGGC-3′,
Reverse, 5′-GGCCTTGACTCACATGCTCT-3′;
DC STAMP:
Forward, 5′-GCTGTATCGGCTCATCTCCT-3′,
Reverse, 5′-AAGGCAGAATCATGGACGAC-3′.
Western Blotting Analysis
Bone marrow macrophages were seeded in 6-well plates at a
density of 6× 105 cells/well. After reaching 90% confluency, cells
were then stimulated with 50 ng/mL RANKL in the presence
or absence of 200 nM flavopiridol in complete α-MEM for 0,
5, 10, 20, 30, or 60 min, immediately followed by washing with
ice-cold PBS to stop the reaction. Total protein was extracted
from cells using radio immune-precipitation assay (RIPA) lysis
buffer (Sigma-Aldrich, St. Louis, MO, United States). Lysates
were centrifuged at 12,000 × g for 15 min, and supernatants
were collected. The protein concentration was determined
using BCA protein assay (Thermo Fisher Scientific). Proteins
were resolved on 10% SDS-PAGE gels and transferred by
electro-blotting to PVDF membranes (Bio-Rad, Hercules, CA,
United States). Membranes were blocked in 5% skim milk in
TBST [50 mM Tris (pH 7.6), 150 mM NaCl, 0.1% Tween 20]
at room temperature for 1 h and then incubated with primary
antibodies diluted in TBST overnight at 4◦C. Membranes were
washed and incubated with horseradish peroxidase-conjugated
goat anti-mouse immunoglobulin G (Abcam, Cambridge, MA,
United States), followed by detection using an electrochemical
luminescence reagent (Millipore, Billerica, MA, United States).
Protein bands were visualized using the LAS-4000 Science
Imaging System (Fujifilm, Tokyo, Japan). Primary antibodies
(Cell Signaling, Danvers, MA, United States) used were:
p65 (rabbit anti-mouse, 1:1000 dilution); phospho-p65 (rabbit
anti-mouse, 1:500 dilution); ERK (rabbit anti-mouse, 1:1000
dilution); p-ERK (rabbit anti-mouse, 1:250 dilution). The
secondary antibody used was goat anti-rabbit IgG (H++L) HRP
(Multisciences, Hangzhou, Zhejiang, China).
Immunofluorescence
Bone marrow macrophages were seeded in 6-well plates at a
density of 6 × 105 cells/well with coverslips on the bottom.
After reaching 90% confluency, cells were then stimulated with
50 ng/mL RANKL in the presence or absence of 200 nM
flavopiridol in complete α-MEM for 1 h, washed three times
with ice-cold PBS, and fixed with 4% paraformaldehyde for
15 min. After fixation, coverslips were removed and placed on
glass slides separately. Samples were blocked with 5% skim milk
for 15 min and incubated with primary antibodies diluted in
blocking buffer at 4◦C overnight. Samples were then washed and
incubated with secondary antibody for 2 h and DAPI for 10 min.
The samples were then washed and mounted with Prolong Gold
Anti-Fade Reagent (Cell Signaling, Danvers, MA, United States),
and fluorescence signal was detected by fluorescence microscopy
(BX51TRF, Olympus, Tokyo, Japan). Primary antibodies were
used as described above and detected with goat anti-rabbit IgG
(H+L), FITC (Multisciences, Hangzhou, Zhejiang, China).
Statistical Analysis
All in vitro experiments were performed in triplicates, all in vivo
experiments have n = 6, and data were expressed as means± SD.
Results were analyzed using SPSS version 16.0 (SPSS, Chicago, IL,
United States). When appropriate, two-tailed, unpaired Student’s
t-test was used to make comparisons between two groups, and
one-way ANOVA for comparisons between multiple samples.
P < 0.05 indicated a significant difference between groups.
RESULTS
Flavopiridol Treatment Reduces Both
Acute Osteolysis and Chronic Estrogen
Deficiency-Induced Osteoporosis
In this study, we evaluated the effects of flavopiridol treatment
using two animal models with bone loss induced by Ti-particles
or ovariectomy. In the Ti-particles model, osteolysis is acutely
induced within 14 days. Loss of bone density at the calvaria
was apparent in the vehicle treated animal group by day 7,
and at day 14 there was extensive bone loss of >50%, when
compared to the sham control (Figures 1A,B). The loss of bone
was confirmed by the increase of trabecular spacing in the vehicle
treated group (Figure 1B). In contrast, flavopiridol treatment
significantly prevented bone loss at all time points tested
when compared to vehicle treatment (Figure 1B). flavopiridol
treatment also prevented the increase in trabecular spacing due
to Ti-particles (Figure 1B). Trabecular number and thickness
were not significantly different between the vehicle and CDK9
inhibition groups (Figure 1B).
The bone protective effect of flavopiridol treatment was
further confirmed by histological analysis of the calvaria
samples (Figure 1C). TRAP staining showed that multinucleated
osteoclasts were significantly increased in the vehicle-treated
group, but their numbers were reduced to a level similar to the
sham control in the CDK9i group (Figure 1C). These results
indicate that flavopiridol treatment prevents osteolysis in the
calvaria by reducing the number of osteoclasts.
In the ovariectomy-induced osteoporosis model, systemic
bone loss is induced by chronic estrogen deficiency and this
allows us to investigate the bone protective effects of flavopiridol
treatment in the long-term. Extensive trabecular bone loss in
the proximal femoral head was observed by µCT in the vehicle-
treated ovariectomy group when compared to the sham control
(Figures 2A,B). However, flavopiridol treatment restored the
trabecular bone density to a level similar to the sham group
(Figure 2A). Similar trend was observed in trabecular number
and thickness (Figure 2B). These results indicate that flavopiridol
treatment is also effective in long-term bone protection.
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FIGURE 1 | Flavopiridol treatment effectively prevents bone resorption in an acute titanium particle-induced osteolysis model. (A) Mice were injected with titanium
particles and treated with vehicle or CDK9 inhibitor flavopiridol (CDK9i). Representative µCT scans of the calvarias at different times are shown. (B) The bone
volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp) derived from µCT scans are shown.
Histograms represent the mean ± standard deviation (n = 6 per group) (∗P < 0.05). (C) Histological assessment of mouse calvarial osteolysis by H&E and TRAP
staining of 14 days’ samples. Arrows indicated TRAP-positive osteoclasts.
Non-cytotoxic Levels of Flavopiridol
Inhibit Osteoclastogenesis in Vitro
Our data suggest that a potential mechanism of flavopiridol
treatment in preventing bone resorption is due to a reduction
in osteoclast numbers (Figure 1C). Other studies have reported
anti-proliferative effects of flavopiridol at concentrations at or
above 300 nM (Aktug et al., 2016; DiPippo et al., 2016; Shafer and
Grant, 2016), which is the targeted plasma concentration for anti-
cancer clinical trials (Senderowicz, 1999). However, studies have
also suggested that the anti-proliferative effect of flavopiridol is
likely due to indiscriminate inhibition of other CDKs that directly
regulate cell-cylce, since only 3 nM of flavopiridol, or 100-
fold less than the anti-proliferative concentration, is sufficient
to inhibit CDK9’s activity (Chao et al., 2000). In light of these
contradicting studies, we determined the cytotoxic profiles of
flavopiridol in osteoclast precursor BMM in order to distinguish
whether flavopiridol’s effects on osteoclastogenesis is due to non-
specific pan-CDKs or specific CDK9 inhibition. BMM cultures
were incubated with different concentrations of flavopiridol for
24, 48, and 72 h, and cell viability was measured and compared to
that of untreated controls (Supplementary Figure 1). There was
no significant cytotoxic effect at doses at or below 200 nM, and
hence flavopiridol was used at 200 nM for the remaining studies.
We next determined the effects of flavopiridol on RANKL-
induced osteoclast differentiation in BMMs. As shown
in Figures 3A–D, flavopiridol significantly inhibited the
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FIGURE 2 | Flavopiridol treatment effectively prevents bone resorption in a chronic overiactomy-induced osteoporosis model. Mice were subjected to overiactomy
and treated with vehicle or CDK9 inhibitor (CDK9i) flavopiridol. (A) The proximal femurs were scanned with µCT at 8 weeks and representative images in different
treatment groups were shown. (B) The bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation
(Tb.Sp) derived from µCT scans were shown. Histograms represent the mean ± standard deviation (n = 6 per group) (∗P < 0.05, paired t-test).
formation of TRAP-positive multinucleated osteoclasts in a
dose-dependent manner. The TRAP-positive cells decreased
from ∼327/well (0 nM flavopiridol) to ∼27/well (200 nM
flavopiridol) (Figure 3E), and the osteoclast-occupied area
dropped from 100% (0 nM flavopiridol) to 4.68% (200 nM
flavopiridol) (Figure 3F). Importantly, flavopiridol at 200 nM or
below did not affect cell proliferation, as the total cell numbers
(undifferentiated BMMs + osteoclasts) determined as cell
density in culture plates were similar in all experimental groups.
Collectively, these data show that 200 nM flavopiridol effectively
inhibited osteoclastogenesis without arresting BMM cell cycle.
Flavopiridol Treatment Suppresses
Osteoclast-Specific Gene Expression
in Vitro
We next examined the effect of flavopiridol treatment on
RANKL-induced mRNA expression of osteoclast-specific genes.
BMMs were stimulated with RANKL in the presence or
absence of 200 nM flavopiridol, and the mRNA expression of
osteoclast-specific genes were then determined by quantitative
PCR. As expected, RANKL treatment induced the expression
of all osteoclast-specific genes by day 5 (Figures 4A–F).
However, CDK9 inhibition significantly suppressed the RANKL-
induced expression of all osteoclast-specific genes. In addition,
housekeeping genes (e.g., 18S, GAPDH, ACTB) were not affected
by flavopiridol treatment, indicating flavopiridol treatment ion
specifically targeted RANKL-induced genes.
Flavopiridol Treatment Prevents
Osteoclastic Bone Resorption in Vitro
We next tested the effects of flavopiridol treatment on osteoclast
function using in vitro bone pit formation assay. Bovine bone
slices were cultured with BMMs and stimulated with RANKL,
with or without 200 nM flavopiridol, and the formation of
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FIGURE 3 | Flavopiridol treatment prevents osteoclastogenesis in vitro. (A–D) BMMs were treated with M-CSF (30 ng/mL), RANKL (50 ng/mL) and the indicated
concentrations of flavopiridol for 5 days. Cells were stained for TRAP. The numbers (E) of TRAP-positive multinuclear cells and the surface areas they occupied
(F) relative to control were determined as described in section “Materials and Methods.” Histograms represent the mean ± standard deviation (n = 3, ∗P < 0.05,
one-way ANOVA). Results indicated that flavopiridol inhibits osteoclastogenesis in a dose-dependent manner.
bone pits were examined by electron microscopy. As expected,
osteoclast numbers, and areas of bone resorption (darker
shades, Figure 5A) were significantly increased after RANKL
stimulation. However, flavopiridol treatment almost completely
abolished the effects of RANKL (Figures 5A–C). Together, these
data show that CDK9 inhibition suppresses osteoclast-mediated
bone resorption in vitro.
Flavopiridol Treatment Suppresses
RANKL-Signaling Pathway via NF-κB
Phosphorylation and Nuclear
Translocation
To elucidate the mechanisms by which flavopiridol treatment
affects RANKL-induced osteoclastogenesis, we investigated
key signaling pathways, including the NF-κB and MAPK
signaling pathways. A time course study was performed on
RANKL-treated BMMs, with or without 200 nM flavopiridol.
The phosphorylation status of the key signaling proteins in
the RANKL pathway, p65 (a component of NF-κB) and
extracellular signal-regulated kinase (ERK), was detected by
Western blotting. As shown in Figure 6A, RANKL treatment
stimulated phosphorylation of both p65 and ERK. In contrast,
CDK9 inhibition significantly attenuated phosphorylation of
p65 (Figures 6A–C). However, flavopiridol treatment generally
didn’t affect phosphorylation of ERK in the current study
(Figures 6A,D,E). These data suggest that CDK9 inhibition
suppresses NF-κB signaling pathways in BMMs.
We next measured nuclear translocation of p65 and
ERK by immunofluorescence staining. The results showed
that RANKL stimulation induced p65 phosphorylation and
nuclear translocation (Figures 6F–H), which was abolished by
flavopiridol treatment (Figure 6F), confirming the Western
blot data above. Taken together, these data suggest that
flavopiridol treatment blocks RANKL signaling pathway by
targeting p65 and NF-κB. Meanwhile, no obvious suppression of
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FIGURE 4 | Flavopiridol treatment suppresses RANKL-induced osteoclast-specific gene expression in vitro. (A–F) Expression of osteoclast-specific genes in BMMs
treated with M-CSF (30 ng/mL), and RANKL (50 ng/mL), and flavopiridol (200 nM) for 1, 3, or 5 days. Gene expression was analyzed by real-time PCR.
Fold-changes in RNA expression for individual genes relative to untreated day 1 controls were normalized to the expression of 18S ribosomal RNA. Histograms
represent the mean ± standard deviation (n = 3, ∗P < 0.05).
FIGURE 5 | Flavopiridol treatment impairs osteoclastic bone resorption in vitro. BMMs were seeded onto bone slices and treated with the same conditions as
described in Figure 4 for 7 days. (A) Representative scanning electron microscopy (SEM) images of bone resorption pits were shown (scale bar = 500 uM).
(B) Resorption pit areas were measured using Image J and (C) the percentage area of osteoclast relative to control was then calculated. Histograms represent the
mean ± standard deviation (n = 3, ∗P < 0.05).
the MAPK signaling pathway was found by CDK9 regulation in
immunofluorescence staining (Figures 6F,I,J).
DISCUSSION
In this study, we determined that CDK9 is important in
osteoclast differentiation and bone resorption function. The bone
protective effect of CDK9 inhibition by flavopiridol treatment
was demonstrated in vivo in two mouse models to examine
conditions that lead to acute (Ti-particles) and chronic (estrogen-
deficiency) bone loss.
Bone remodeling is a characteristic in many disease
progressions, for example, during osteoarthritis pathogenesis.
In a previous study using a mouse model of knee injury, injury-
induced inflammation caused a rapid loss of tibia epiphysis
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FIGURE 6 | Flavopiridol treatment prevents osteoclastogenesis by targeting RANKL-induced NF-κB pathway. (A) BMMs were treated with 50 ng/mL RANKL in the
presence or absence of 200 nM flavopiridol for 0-, 5-, 10-, 20-, 30-, and 60-min. The expression of total and phosphorylated p65, ERK, and β-actin was determined
by Western blot. Images of bands were grouped together. (B–E) The intensity of each protein band was quantified and normalized to β-actin using Image J (n = 3,
∗P < 0.05). (F) BMMs were treated with CDK9 inhibitor (200 nM), M-CSF (30 ng/mL), and RANKL (50 ng/mL) for 1 h and total and phosphorylated p65 and ERK
was detected by immunofluorescence imaging. Nuclear positions were marked by DAPI. (G–J) The fluorescence intensity of p65 and ERK in different samples was
quantified with Image J. The signal of RANKL only samples was set to 100%. The nucleus VS cytoplasm signal intensity ratio of p-P65 and p-ERK was calculated to
indicate the nucleus translocation (results were the mean ± standard deviation, ∗P < 0.05).
trabecular bone mass (up to 30–40%) within 7 days of injury.
This was followed by a gradual but only partial recovery
(to ∼80%) of the original bone tissue by day 30 post-injury
(Christiansen et al., 2015), indicating a bone-remodeling event
occurs after a knee injury. The new bone formed from the
remodeling was thinner and fenestrated due to a decrease in
mineral density, which is associated with a reduction in the elastic
moduli and bone strength (Mahjoub et al., 2012). In this case,
preventing the bone loss/remodeling from happening in the first
place is perhaps more beneficial than promoting the subsequent
regaining of weaker bone tissue. Indeed, this study demonstrated
that treatment with the CDK9 inhibitor flavopiridol effectively
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prevented bone loss in two clinical relevant mouse models of
acute and chronic induced bone loss. To our knowledge, this is
the first detail report showing that flavopiridol treatment may
be an effective treatment strategy for both clinical conditions
of wear particle-induced osteolysis, and estrogenic-deficiency
induced osteoporosis.
Under pathological conditions, the process of
osteoclastogenesis is initiated by various innate and acquired
mediators, including pro-inflammatory cytokines, which act
on osteoclast precursors directly or indirectly, through the
RANK/RANKL axis (Boyce and Xing, 2008; Xing et al., 2012).
A previous study has shown that even a small rise in the level
of systemic inflammation can precipitate osteodestruction
(Sucur et al., 2014). Thus, investigation of factors that promote
osteoclast activity may provide insight into the pathological
events responsible for bone loss. In cases of acute bone osteolysis
(Yang et al., 2016), joint injury (Yik et al., 2014; Hu et al.,
2016), intervertebral disk degeneration (Wuertz et al., 2012)
and osteoporosis (Adler et al., 2016), an exogenous stimulation
triggers the secretion of various cytokines. Secreted cytokines
include TNF-α, interleukin-1, interleukin-6, prostaglandin
E2, and matrix metalloproteinases. These cytokines and
factors induce inflammation and subsequently induce RANKL
production by osteocytes, followed by recruitment of osteoclast
precursors to the bone surface to initiate bone resorption.
Current anti-resorptive drugs available include
bisphosphonates (e.g., Alendronate, Risedronate), calcitonin,
selective estrogen receptor modulators (SEMRs), RANKL
antibody (Denosumab) and Cathepsin-K inhibitor (Odanacatib)
(Adler et al., 2016; Pazianas and Abrahamsen, 2016). However,
side effects such as fever, throat and stomach ulcers, breast
cancer, thromboembolism, hypercalcemia and hypertention,
and also the bioavailability limit the use of these drugs in
systemic treatment (Tian et al., 2014). Furthermore, despite
these anti-resorptive drugs’ ability to reduce the risk of vertebral
fractures by up to 70%, and hip fractures by 40–50%, there is
only a 20–25% risk reduction for all other non-vertebral fractures
(Díez-Pérez et al., 2014). Therefore, there is clinical demand for
new therapeutic strategies, such as utilizing the bone protective
effect of flavopiridol treatment to reduce fracture risk.
The interaction with RANKL induces trimerization of cell
surface receptor RANK on osteoclast precursors (Xing, 2009;
Xing et al., 2012), and subsequently activates TNF receptor
associated factor 6 (TRAF6). This activates a cascade of
intracellular events, such as the activation of NF-κB, mitogen-
activated protein kinases (MAPKs), and the nuclear factor of
activated T-cells 1 (NFATc1) signaling pathways, all of which
are essential for osteoclast formation (Boyce et al., 2015).
The classical NF-κB activation involves phosphorylation and
degradation of IκBα, which then allows phosphorylation of
NF-κB protein (such as p65) and its nuclear translocation
to bind to DNA target sites to activate the expression of
osteoclastogenesis-related genes (Abu-Amer, 2013). Genetic
studies have confirmed that p65-knockout results in osteopetrosis
due to the lack of osteoclast formation, demonstrating the
essential role of NF-κB signaling in osteoclast differentiation
(Boyce and Xing, 2008). Importantly, CDK9 interacts with
p65 in the nucleus to modulate HIV-1 gene (Amini et al.,
2002) and pro-inflammatory cytokine genes transcription
(Brasier, 2008). Collectively, these studies suggest an inter-
relationship between CDK9, NF-κB, and RANKL signaling
pathway to regulate osteoclast differentiation. In this study,
we confirmed that RANKL stimulation markedly activated
NF-κB signaling pathway by phosphorylating p65 in BMM
cells; however, flavopiridol treatment effectively suppressed p65
phosphorylation and nuclear translocation (Figure 6). As a
result, osteoclastogenesis (Figure 3), osteoclast-specific gene
expression (Figure 4), and osteoclast functions (Figure 5) were
all suppressed in the presence of CDK9 inhibitors. Importantly,
the above observation was made using non-cytotoxic levels of
flavopiridol. Thus, our results provide strong evidence that the
bone protective effects of flavopiridol is due to its inhibition
of CDK9 activity (but not other CDKs,), which in turn is
required for activation of RANKL and NF-κB signaling for
osteoclastogenesis. In support of this, our previous result using
CDK9 siRNA demonstrated that the anti-inflammatory activity
of flavopiridol is due to specific inhibition of CDK9, but
not other CDKs that regulate cell-cycle (Yik et al., 2014),
which was also proved by another group (Oqani et al.,
2011).
Various downstream effector genes are involved in the process
of NF-κB (Boyce et al., 2010) activation, and among those genes,
c-Fos and NFATc1 are the most important (Boyce et al., 2015).
c-Fos is a major component of the transcription factor AP-1,
which induces NFATc1, a master regulator of osteoclastogenesis,
to regulate osteoclast formation (Iezaki et al., 2016). This explains
our observation that inhibition of NF-κB by CDK9 inhibitors
resulted in suppression of RANKL-induced c-Fos, and NFATc1,
as well as the suppression of downstream osteoclast-specific
markers such as TRAP, CTR, DC-Stamp, and CTSK.
There are potential limitations in this study. First, CDK9
also acts as a crucial transcription factor for other inducible
genes. Therefore, we cannot exclude the possibility that besides
NK-κB and RANKL, other unknown mediators and signaling
pathways are also involved in flavopiridol-mediated repression
of osteoclastogenesis. In addition, our study is limited to bone
remodeling involving the calvaria and femur. Other skeletal
system, such as the vertebral region, will need to be examined to
broaden the implication and potential clinical applications.
In summary, our study conclusively demonstrates that
flavopiridol treatment prevents bone loss in both acute and
chronic induced bone loss mouse models. Flavopiridol treatment
effectively suppresses osteoclastogenesis, osteoclast-specific gene
expression, and osteoclast function in vitro. The mechanism
of flavopiridol’s bone protective effects is in part due to its
suppression of NF-κB and RANKL signaling pathways. Our study
demonstrates that CDK9 is a potential therapeutic target for
disease modifying treatment of bone-related illness.
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